PEN - Penumbra - Stock Forecast

Healthcare - Sector

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

PEN is currently covered by 12 analysts with an average price target of $343.65. This is a potential upside of $43.87 (14.63%) from yesterday's end of day stock price of $299.78.

Penumbra's activity chart (see below) currently has 161 price targets and 181 ratings on display. The stock rating distribution of PEN is 85% BUY and 15% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 85.34% with an average time for these price targets to be met of 116.67 days.

Highest price target for PEN is $330, Lowest price target is $245, average price target is $302.8.

Most recent stock forecast was given by DAVID RESCOTT from BAIRD on 24-Apr-2025. First documented stock forecast 13-Oct-2015.

Best performing analysts who are covering PEN - Penumbra:

Mike Matson Brandon Henry David Rescott Robbie Marcus William Plovanic Richard Newitter Ryan Zimmerman Sanjit Singh Pito Chickering Matt O'brien

Currently out of the existing stock ratings of PEN, 68 are a BUY (85%), 12 are a HOLD (15%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

David Rescott (BAIRD)

Buy

$325

$25.22 (8.41%)

$315

3 days ago
(24-Apr-2025)

17/25 (68%)

$26.75 (8.97%)

166

Please subscribe to see the analyst performance score

Mike Matson (NEEDHAM)

Hold

2 months 8 days ago
(19-Feb-2025)

3/3 (100%)

$32.62 (12.20%)

Please subscribe to see the analyst performance score

Matt O'brien (PIPER SANDLER)

Buy

$330

$30.22 (10.08%)

$250

2 months 8 days ago
(19-Feb-2025)

9/11 (81.82%)

$58.86 (21.71%)

Please subscribe to see the analyst performance score

Richard Newitter (TRUIST)

Buy

$285

$-14.78 (-4.93%)

$235

4 months 9 days ago
(18-Dec-2024)

4/4 (100%)

$46.1 (19.30%)

Please subscribe to see the analyst performance score

Joanne Wuensch (CITI)

Hold

$245

$-54.78 (-18.27%)

$200

4 months 16 days ago
(11-Dec-2024)

21/23 (91.3%)

$-8.66 (-3.41%)

209

Please subscribe to see the analyst performance score

Show more analysts

Load Price Targets and Ratings Chart

To gain access for the analyst/ stock price target chart please use a computer

What is PEN (Penumbra) average time for price targets to be met?

On average it took 116.67 days on average for the stock forecasts to be realized with a an average price target met ratio 85.34

Which analyst has the current highest performing score on PEN (Penumbra) with a proven track record?

MIKE MATSON

Which analyst has the most public recommendations on PEN (Penumbra)?

Mike Matson works at NEEDHAM and has 36 price targets and 37 ratings on PEN

Which analyst is the currently most bullish on PEN (Penumbra)?

Sanjit Singh with highest potential upside - $112.33

Which analyst is the currently most reserved on PEN (Penumbra)?

Brandon Henry with lowest potential downside - -$73.67

Penumbra in the News

3 Reasons PEN is Risky and 1 Stock to Buy Instead

3 Reasons PEN is Risky and 1 Stock to Buy Instead In a sliding market, Penumbra has defied the odds, trading up to $255.82 per share. Its 29.5% gain since October 2024 has outpaced the S&P 500’s 13.6% drop. This was partly due to its solid quarterly results, and the run-up might have investors contemplating...

Reasons to Retain Penumbra Stock in Your Portfolio for Now

Penumbra, Inc.’s PEN thrombectomy business is thriving, driven by growing sales of the U.S. vascular thrombectomy and CAVT (computer-assisted vacuum thrombectomy) line of products. The company’s robust product portfolio expansion is poised to drive growth in the upcoming quarters. Meanwhile, unfavorable foreign exchange and intense competition may pose operational risks for PEN. In the past...